Cytokine Therapy for RCC: What's next for research after the Bempeg trial disappointment?

Welcome to KidneyCANDID, where we explore topics for patients, caregivers, researchers, and clinicians. We'll be sharing quick, informal videos created by those who live and deal with #kidneycancer every day. We all long for an immunotherapy complete response for kidney cancer patients. The cytokine Il2 has been an option, but the inpatient requirements mean it's rarely used now. The disappointing failure of the Bempeg+Nivolumab PIVOT IO-001 trial left us wondering: "What happened? Do cytokines have a future for treating kidney cancer?" Georgetown Lombardi Comprehensive Cancer Center's Michael Serzan talks about lessons from these trial results and next steps for cytokine development for RCC. Have a KidneyCANDID topic you'd like to see us tackle? Let us know by emailing [email protected] with KidneyCANDID Topic in the subject line. ————————————————————————— KidneyCAN works to accelerate cures for kidney cancer by providing patient support and education, encouraging enrollment in clinical trials, advocating for research funding from Congress, and sponsoring collaborative efforts between researchers and medical communities. To learn more about KidneyCAN: https://kidneycan.org​ Support our work: https://kidneycan.org/donate